Platform technology
Developing Targeted Therapies With no Compromise
SagittaTM Bir and SagittaTM Dui are discovered to address this challenge with biodegradable conjugation platforms that reinforce ideal performances in terms of the therapeutic index, PK and manufacturability.
SagittaTM
Developing Targeted Therapies With no Compromise
SagittaTM Bir and SagittaTM Dui are discovered to address this challenge with biodegradable conjugation platforms that reinforce ideal performances in terms of the therapeutic index, PK and manufacturability.
The lead candidate: RS-0139
Upon contact with water, SagittaTM Bir backbone wraps around the payload, ensuring formation of a water soluble nanocarrier.
The lead candidate: RS-0337
Upon contact with water, SagittaTM Dui forms a micellar nanoparticle, encapsulating the second payload.
Therapeutic Index
The dual drug loading capacity of SagittaTM yields to a synergistic therapeutic effect. SagittaTM platform is compatible with a wide range of targeting ligands or mAbs as well as a diverse choice of drugs – ensuring highest efficacy and specificity.
Pharmacokinetics
SagittaTM platform significantly prolongs the circulation time compared to native API. The improvement in half-life translated across species and therefore poses predictable promise for later clinical stages.
Manufacturing
HIGHER
THERAPEUTIC INDEX
The dual drug loading capacity of SagittaTM yields to a synergistic therapeutic effect. SagittaTM platform is compatible with a wide range of targeting ligands or mAbs as well as a diverse choice of drugs – ensuring highest efficacy and specificity.
IMPROVED
PHARMACOKINETICS
SagittaTM platform significantly prolongs the circulation time compared to native API. The improvement in half-life translated across species and therefore poses predictable promise for later clinical stages.
STRAIGHT-FORWARD
MANUFACTURING
We manufacture our products at our own GMP certificated production facility for clinical batch lyophilized oncology drugs.
